Sodium glucose cotransporter 2 (SGLT2) inhibitors, such as empagliflozin, dapagliflozin,
ertugliflozin and canagliflozin, increase urinary excretion of glucose by inhibiting …

Abstract Sodium-glucose cotransporter-2 inhibitors (SGLT2i) are a class of oral glucose-
lowering agents commonly used for the treatment of type 2 diabetes. With increased use …

Objective Due to the growing diabetes pandemic, the number of colonoscopies performed in
patients with diabetes is steadily rising. However, recommendations on adjustments of anti …

Objective (s). Diabetic ketoacidosis (DKA) is a rare but well‐known complication of sodium‐
glucose transporter inhibitor (SGLT2i) treatment in patients with type 2 diabetes. The …

The article discusses research which reviewed the colonoscopy records of type 2 diabetes
(T2D) patients to determine the incidence of pericolonoscopy hyperketonemia in T2D …

Objective To determine the relationship between point‐of‐care β‐hydroxybutyrate (BHB)
concentration and outcomes in adult patients without diabetes admitted through ED …

Objective Sodium-glucose co-transporter-2 inhibitors (SGLT2i) are associated with risk of
euglycemic ketoacidosis. Guidelines recommend withholding SGLT2i prior to surgery and …

Elevated blood ketone levels (ketosis) in inpatients with diabetes can herald diabetic
ketoacidosis (DKA). However, ketosis can also occur in individuals without diabetes in …

Trypanosoma cruzi, the etiological agent of Chagas disease, is an intracellular protozoan
parasite, which is now present in most industrialized countries. About 40% of T. cruzi …

The study on sodium–glucose cotransporter 2 inhibitor (SGLT2i) therapy by Hamblin et al.(1)
advocates for increasing b-hydroxybutyrate (BHB) to 1.7 mmol/L for hyperketonemia, in …